OccuRx is a biopharmaceutical company focused on innovative therapeutic strategies for ocular diseases associated with inflammation and fibrosis.
OccuRx has identified and validated a series of lead candidates against novel targets and established preclinical proof of concept to treat and prevent ocular fibrosis. The Company is leveraging these proprietary small molecule drugs to address the unmet clinical need for more targeted ocular therapies to enhance visual acuity and prevent vision loss in inflammatory and degenerative eye disease. OCX063, our most advanced lead product candidate, is a small molecule drug with the potential to prevent the growth of new and abnormal blood vessels, reduce inflammation of the neurons in the retina.
These pathological processes, if not treated, will lead the eventual formation of scar tissue in the back of the eye that results in severe vision loss in diabetic retinopathy (DR) and wet age-related macular degeneration (wet AMD). OccuRx was established in 2014 with venture funding from the Medical Research Commercialisation Fund, Brandon Capital Partners and Uniseed.
OccuRx is advancing proprietary small molecule lead candidates against novel therapeutic targets for ocular inflammation and fibrosis in sight threatening eye disease, including diabetic retinopathy, wet age-related macular degeneration, and severe dry eye syndrome.